Respiratory syncytial virus infection: survival experience in a cohort of children inpatients

Objective: The objective of this study was to assess the survival experience of children hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infection due to bronchiolitis.Study design: This was a nationwide retrospective cohort study conducted in Mexico.Methods: We analyzed data from 436 children aged 5 years and younger, with symptom onset between August 2021 and November 2022. The Kaplan-Meier method was used to compute survivor functions and their 95% confidence intervals (CI).Results: High survival rates were observed, particularly within the first three weeks of hospital admis-sion. The 3-day survival rate was 99.8% (CI 98.4-99.9%), which decreased to 98.9% (CI 96.5-99.7%), 97.5% (CI 91.9-99.3%), 86.7% (CI 48.2-97.2%), and 69.4% (CI 24.2-91.0%) on days 7, 14, 21, and 28 of hospital stay, respectively. We documented a total of 5 fatal outcomes, resulting in a mortality rate of 2.1 (95% CI 0.9-5.1) per 1,000 person-days.Conclusions: Our study analyzed a large cohort of pediatric patients with bronchiolitis caused by RSV infection, providing valuable insights into the in-hospital progression of this disease.& COPY; 2023 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.

Automated summary

The objective of this study was to assess the survival experience of children hospitalized with laboratory-confirmed respiratory syncytial virus (RSV) infection due to bronchiolitis. A nationwide retrospective cohort study was conducted in Mexico, analyzing data from 436 children aged 5 years and younger. High survival rates were observed within the first three weeks of hospital admission, with a mortality rate of 2.1 per 1,000 person-days.